Abstract
Multiparametric MRI (mpMRI) is increasingly used as part of the diagnostic evaluation for prostate cancer (PCa). While mpMRI with targeted biopsy appears to increase the detection of clinically-significant cancer and reduce overdiagnosis of low-risk cancer,1 a substantial proportion of Grade Group ≥2 (GG ≥2) lesions are not visible on mpMRI.2,3 The clinical significance of mpMRI-invisible lesions remains unclear, and limited data exist describing the course of mpMRI-negative PCa.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
